Overview

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Diagnosed with primary open-angle glaucoma or ocular hypertension.

- Provided signed, written informed consent.

- If a subject is a female of childbearing potential, she must utilize reliable
contraceptive throughout the study, and must have a negative urine pregnancy test
prior to enrollment into this study.

Exclusion Criteria:

- Females who are pregnant, nursing or planning a pregnancy, or females of childbearing
potential who are not using a reliable method of contraception.

- Presence of any abnormality or significant illness that could be expected to interfere
with the study.